Publications by authors named "Lloyd Haskell"

Claim this Profile
R
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Shea Hogan, Michael Szarek, E Sebastian Debus, Mark Nehler, Sonia S Anand, Lloyd P Haskell

J Am Heart Assoc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial.
R Kevin Rogers, Eike Sebastian Debus, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell

JACC Cardiovasc Interv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.
Mario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, E Sebastian Debus, Mark R Nehler, Lloyd P Haskell

J Am Coll Cardiol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
George Bakris, Cindy Chen, Alicia K Campbell, Veronica Ashton, Lloyd Haskell

Am J Hypertens· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Justin T Morrison, Mario Enrico Canonico, Sonia S Anand, Manesh R Patel, Eike Sebastian Debus, Lloyd P Haskell

Circulation· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD.
R Kevin Rogers, Joerg Herold, Nicholas Govsyeyev, Roberto Iezzi, Justin Morrison, Lloyd P Haskell

Vasc Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Lloyd Haskell

J Am Heart Assoc· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD.
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Lloyd P Haskell

Circulation· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Jennifer Rymer, Sonia S Anand, E Sebastian Debus, Lloyd P Haskell, Connie N Hess

Circulation· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.
George Bakris, Cindy Chen, Alicia K Campbell, Veronica Ashton, Lloyd Haskell

J Clin Hypertens (Greenwich)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.
Albert A Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S Barnathan

Am J Cardiovasc Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Nicholas Govsyeyev, Mark Nehler, Michael S Conte, Sebastian Debus, Jayer Chung, Lloyd P Haskell

J Vasc Surg· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US.
Eric M Ammann, Ellen S O'Brien, Dejan Milentijevic, Akshay A Kharat, Darren A Talbot, Lloyd Haskell

Heliyon· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Marc P Bonaca, Michael Szarek, E Sebastian Debus, Mark R Nehler, Manesh R Patel, Lloyd P Haskell

Clin Cardiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Markus P Schlaich, Marc Bellet, Michael A Weber, Parisa Danaietash, George L Bakris, Lloyd P Haskell

Lancet· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.
Shea E Hogan, Mark R Nehler, Sonia Anand, Manesh R Patel, Sebastian Debus, Lloyd P Haskell

Vasc Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Connie N Hess, Iris Baumgartner, Sonia S Anand, Mark R Nehler, Manesh R Patel, Lloyd P Haskell

J Am Heart Assoc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
Connie N Hess, Michael Szarek, Sonia S Anand, Rupert M Bauersachs, Manesh R Patel, Lloyd P Haskell

JAMA Netw Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Sonia S Anand, Will Hiatt, Leanne Dyal, Rupert Bauersachs, Scott D Berkowitz, Lloyd P Haskell

Eur J Prev Cardiol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
Scott D Berkowitz, Rupert M Bauersachs, Michael Szarek, Mark R Nehler, E Sebastian Debus, Lloyd P Haskell

J Thromb Haemost· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Concetta Lipardi, C Gregory Elliott, Chiara L Sugarmann, Lloyd Haskell, Alex C Spyropoulos

Clin Appl Thromb Hemost· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Connie N Hess, E Sebastian Debus, Mark R Nehler, Sonia S Anand, Manesh R Patel, Lloyd P Haskell

Circulation· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Connie N Hess, Manesh R Patel, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Lloyd P Haskell

J Am Coll Cardiol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Mori J Krantz, Sebastian E Debus, Judith Hsia, Manesh R Patel, Sonia S Anand, Lloyd P Haskell

Eur Heart J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial.
Judith Hsia, Michael Szarek, Sonia Anand, Manesh R Patel, Sebastian Debus, Lloyd P Haskell

J Am Coll Cardiol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis